AstraZeneca said it has reached an agreement in principle with U.S. attorney's office in Philadelphia to resolve an investigation related to its schizophrenia drug Seroquel sales and marketing practices.
The investigation has also scrutinized "selected physicians who participated in clinical trials involving Seroquel," the company said, adding that the investigations are the subject of two sealed whistleblower lawsuits filed under the False Claims Act.
The settlement accounts for $520 million of the $538 million provisions taken in the first nine months of the year, it said.
No comments:
Post a Comment